AADI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AADI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aadi Bioscience's Enterprise Value is $-2.03 Mil. Aadi Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-56.43 Mil. Therefore, Aadi Bioscience's EV-to-FCF for today is 0.04.
The historical rank and industry rank for Aadi Bioscience's EV-to-FCF or its related term are showing as below:
During the past 4 years, the highest EV-to-FCF of Aadi Bioscience was 161.81. The lowest was -16.22. And the median was -0.91.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-13), Aadi Bioscience's stock price is $2.41. Aadi Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.280. Therefore, Aadi Bioscience's PE Ratio (TTM) for today is At Loss.
The historical data trend for Aadi Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aadi Bioscience Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EV-to-FCF | - | -15.85 | -2.85 | 0.91 |
Aadi Bioscience Quarterly Data | |||||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | -0.01 | 0.91 | 0.48 | 0.78 | 0.19 |
For the Biotechnology subindustry, Aadi Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aadi Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aadi Bioscience's EV-to-FCF falls into.
Aadi Bioscience's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | -2.026 | / | -56.425 | |
= | 0.04 |
Aadi Bioscience's current Enterprise Value is $-2.03 Mil.
Aadi Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aadi Bioscience (NAS:AADI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aadi Bioscience's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 2.41 | / | -2.280 | |
= | At Loss |
Aadi Bioscience's share price for today is $2.41.
Aadi Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Aadi Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
David James Lennon | director, officer: Chief Executive Officer | C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272 |
Neil Desai | director, officer: See Remarks | C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272 |
Mohammad Hirmand | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Scott M. Giacobello | officer: Chief Financial Officer | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
Lorettta M Itri | officer: Chief Medical Officer | |
Brendan Delaney | officer: Chief Operating Officer | 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950 |
Emma Reeve | director | C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
Karin M. Hehenberger | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803 |
Richard E Maroun | director | C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272 |
Caley Castelein | director | THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104 |
Lance E Thibault | officer: Chief Financial Officer | |
Behzad Aghazadeh | director, other: See Remarks | C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Venbio Select Advisor Llc | director, other: See Remarks | 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Anupam Dalal | director | 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108 |
Avoro Ventures Llc | director, other: See Remarks | 110 GREEN STREET, SUITE 800, NEW YORK NY 10012 |
From GuruFocus
By GuruFocus Research • 03-14-2024
By GuruFocus Research • 02-05-2024
By GuruFocus Research • 02-05-2024
By GuruFocus Research • 02-05-2024
By GuruFocus Research • 02-05-2024
By PRNewswire • 10-30-2024
By PRNewswire • 05-23-2024
By PRNewswire • 05-01-2024
By PRNewswire • 03-04-2024
By GuruFocus Research • 02-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.